Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Yonsei Med J. 2012 Sep;53(5):875-85. doi: 10.3349/ymj.2012.53.5.875.

Hepatitis B precore protein: pathogenic potential and therapeutic promise.

Author information

  • 1Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia. renae.walsh@mh.org.au

Abstract

Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the host's immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB and liver disease.

PMID:
22869468
[PubMed - indexed for MEDLINE]
PMCID:
PMC3423855
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Yonsei University College of Medicine Icon for PubMed Central
    Loading ...
    Write to the Help Desk